Across TCGA pan-cancer cohorts, RN7SL252P RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of RN7SL252P’s most consistent transcriptional readouts.
The strongest signal is observed in thyroid carcinoma (THCA), where RN7SL252P RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RN7SL252P is over-expressed in tumor.
THCA are the cancer types where RN7SL252P tumor–normal differential expression is most reproducible.